NL301202I2 - Linzagolix, of een farmaceutisch aanvaardbaar zout daarvan, zoals linzagolix choline - Google Patents

Linzagolix, of een farmaceutisch aanvaardbaar zout daarvan, zoals linzagolix choline

Info

Publication number: NL301202I2
Authority: NL; Netherlands
Prior art keywords: linzagolix; choline; pharmaceutically acceptable; acceptable salt; salt
Prior art date: 2005-10-19

Application number

NL301202C

Other languages

English (en)

Other versions

NL301202I1 (nl

Original Assignee

Kissei Pharmaceutical

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-10-19

Filing date

2022-11-01

Publication date

2023-01-24

2022-11-01 Application filed by Kissei Pharmaceutical filed Critical Kissei Pharmaceutical

2022-11-09 Publication of NL301202I1 publication Critical patent/NL301202I1/nl

2023-01-24 Publication of NL301202I2 publication Critical patent/NL301202I2/nl

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
- A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens

NL301202C 2005-10-19 2022-11-01 Linzagolix, of een farmaceutisch aanvaardbaar zout daarvan, zoals linzagolix choline NL301202I2 (nl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
JP2005304395		2005-10-19
JP2006147019		2006-05-26
PCT/JP2006/320681 WO2007046392A1 (ja)	2005-10-19	2006-10-17	縮合複素環誘導体、それを含有する医薬組成物及びその医薬用途

Publications (2)

Publication Number	Publication Date
NL301202I1 NL301202I1 (nl)	2022-11-09
NL301202I2 true NL301202I2 (nl)	2023-01-24

Family

ID=37962485

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NL301202C NL301202I2 (nl)	2005-10-19	2022-11-01	Linzagolix, of een farmaceutisch aanvaardbaar zout daarvan, zoals linzagolix choline

Country Status (21)

Country	Link
US (1)	US9040693B2 (nl)
EP (1)	EP1939204B3 (nl)
JP (2)	JP4955566B2 (nl)
KR (1)	KR101384132B1 (nl)
AU (1)	AU2006305271B2 (nl)
BR (1)	BRPI0617436B8 (nl)
CA (1)	CA2624492C (nl)
CY (1)	CY1113898T1 (nl)
DK (1)	DK1939204T6 (nl)
ES (1)	ES2398917T7 (nl)
HK (1)	HK1125110A1 (nl)
IL (1)	IL190754A (nl)
NL (1)	NL301202I2 (nl)
NO (1)	NO343185B1 (nl)
NZ (1)	NZ567300A (nl)
PL (1)	PL1939204T6 (nl)
PT (1)	PT1939204E (nl)
RU (1)	RU2418803C2 (nl)
SI (1)	SI1939204T1 (nl)
TW (1)	TWI400074B (nl)
WO (1)	WO2007046392A1 (nl)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8263588B2 (en) *	2007-04-06	2012-09-11	Neurocrine Biosciences, Inc.	Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
CN101678007B (zh)	2007-04-06	2013-07-03	纽罗克里生物科学有限公司	***释放激素受体拮抗剂及其制药用途
CA2682400A1 (en) *	2007-04-18	2008-11-06	Kissei Pharmaceutical Co., Ltd.	Fused heterocyclic derivative, pharmaceutical composition comprising the derivative, and use of the composition for medical purposes
EP2147922B1 (en)	2007-04-18	2017-08-02	Kissei Pharmaceutical Co., Ltd.	Fused heterocyclic derivative, pharmaceutical composition comprising the derivative, and use of the composition for medical purposes
KR101631143B1 (ko)	2010-02-10	2016-06-17	깃세이 야쿠힌 고교 가부시키가이샤	축합 복소환 유도체의 염 및 그 결정
WO2014030743A1 (ja)	2012-08-24	2014-02-27	武田薬品工業株式会社	複素環化合物
JP6268093B2 (ja) *	2012-09-14	2018-01-24	キッセイ薬品工業株式会社	縮合複素環誘導体の製造方法およびその製造中間体
JP6574444B2 (ja) *	2014-01-06	2019-09-11	ブリストル−マイヤーズスクイブカンパニーＢｒｉｓｔｏｌ−ＭｙｅｒｓＳｑｕｉｂｂＣｏｍｐａｎｙ	炭素環式スルホンＲＯＲγ調節因子
AU2017309015B2 (en) *	2016-08-08	2022-09-15	Kissei Pharmaceutical Co., Ltd.	Administration and dosage of therapeutic agent for endometriosis
WO2018144603A1 (en) *	2017-01-31	2018-08-09	Veru Inc.	COMPOSITIONS AND METHODS FOR LONG TERM RELEASE OF GANADOTROPIN-RELEASING HORMONE (GnRH) ANTAGONISTS
EP3634419A1 (en)	2017-06-05	2020-04-15	ObsEva S.A.	Gonadotropin-releasing hormone antagonist dosing regimens for treating uterine fibroids and reducing menstrual blood loss
CA3066190A1 (en)	2017-06-05	2018-12-13	ObsEva S.A.	Gonadotropin-releasing hormone antagonist dosing regimens for the treatment of endometriosis
EP4086245A1 (en) *	2018-01-30	2022-11-09	Incyte Corporation	Processes for preparing intermediates for the synthesis of a jak inhibitor
US20220117969A1 (en)	2018-10-29	2022-04-21	ObsEva S.A.	Compositions and methods for the treatment of adenomyosis and rectovaginal endometriosis
US20230067378A1 (en)	2018-11-07	2023-03-02	ObsEva S.A.	Compositions and methods for the treatment of estrogen-dependent disorders
KR20220045198A (ko) *	2019-08-08	2022-04-12	옵스에파 에스에이	에스트로겐-의존성 장애의 치료를 위한 gnrh 길항제
KR20220061120A (ko)	2019-08-08	2022-05-12	옵스에파 에스에이	에스트로겐-의존성 장애 치료용 조성물 및 방법
WO2022179469A1 (zh) *	2021-02-23	2022-09-01	南京明德新药研发有限公司	噻吩并嘧啶二酮类化合物及其应用
JP2024507408A (ja) *	2021-02-23	2024-02-19	ソーター・バイオファーマ・プライベイト・リミテッド	縮合多環式置換５－カルボン酸チエノピリミジンジオン化合物およびその使用
WO2024037532A1 (zh) *	2022-08-16	2024-02-22	深圳市康哲生物科技有限公司	一种噻吩并嘧啶酮衍生物的盐型及晶型

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0781774B1 (en)	1995-12-08	2002-07-31	Takeda Chemical Industries, Ltd.	Prolactin production inhibitory agents
WO1997040846A1 (en)	1996-04-30	1997-11-06	Takeda Chemical Industries, Ltd.	COMBINED USE OF GnRH AGONIST AND ANTAGONIST
WO1997044339A1 (en)	1996-05-20	1997-11-27	Merck & Co., Inc.	Antagonists of gonadotropin releasing hormone
GB0124627D0 (en)	2001-10-15	2001-12-05	Smithkline Beecham Plc	Novel compounds
EP1687306A1 (en) *	2003-11-14	2006-08-09	MERCK SHARP & DOHME LTD.	Bicyclic pyrimidin-4-(3h)-ones and analogues and derivatives thereof which modulate the function of the vanilloid-1 receptor (vr1)
JP2007514757A (ja)	2003-12-19	2007-06-07	メルク　エンド　カムパニー　インコーポレーテッド	有糸***キネシン阻害剤
JPWO2006083005A1 (ja)	2005-02-03	2008-06-26	武田薬品工業株式会社	縮合ピリミジン誘導体およびその用途

2006
- 2006-10-17 ES ES06811925T patent/ES2398917T7/es active Active
- 2006-10-17 RU RU2008119462/04A patent/RU2418803C2/ru active
- 2006-10-17 DK DK06811925.4T patent/DK1939204T6/da active
- 2006-10-17 WO PCT/JP2006/320681 patent/WO2007046392A1/ja active Application Filing
- 2006-10-17 JP JP2007540993A patent/JP4955566B2/ja active Active
- 2006-10-17 SI SI200631557T patent/SI1939204T1/sl unknown
- 2006-10-17 KR KR1020087010997A patent/KR101384132B1/ko active IP Right Grant
- 2006-10-17 PL PL06811925.4T patent/PL1939204T6/pl unknown
- 2006-10-17 NZ NZ567300A patent/NZ567300A/en unknown
- 2006-10-17 AU AU2006305271A patent/AU2006305271B2/en active Active
- 2006-10-17 BR BRPI0617436A patent/BRPI0617436B8/pt active IP Right Grant
- 2006-10-17 EP EP06811925.4A patent/EP1939204B3/en active Active
- 2006-10-17 PT PT68119254T patent/PT1939204E/pt unknown
- 2006-10-17 CA CA2624492A patent/CA2624492C/en active Active
- 2006-10-17 US US12/089,674 patent/US9040693B2/en active Active
- 2006-10-19 TW TW095138520A patent/TWI400074B/zh active
2008
- 2008-04-09 IL IL190754A patent/IL190754A/en active IP Right Grant
- 2008-05-19 NO NO20082249A patent/NO343185B1/no unknown
2009
- 2009-04-09 HK HK09103380.3A patent/HK1125110A1/xx unknown
2012
- 2012-01-19 JP JP2012008680A patent/JP5319797B2/ja active Active
2013
- 2013-04-02 CY CY20131100276T patent/CY1113898T1/el unknown
2022
- 2022-11-01 NL NL301202C patent/NL301202I2/nl unknown

Also Published As

Publication number	Publication date
BRPI0617436B1 (pt)	2021-04-06
EP1939204A4 (en)	2010-09-01
NZ567300A (en)	2010-11-26
ES2398917T3 (es)	2013-03-22
EP1939204B3 (en)	2022-08-24
CY1113898T1 (el)	2016-07-27
DK1939204T3 (da)	2013-03-11
PL1939204T6 (pl)	2024-03-25
CA2624492A1 (en)	2007-04-26
HK1125110A1 (en)	2009-07-31
IL190754A0 (en)	2008-11-03
BRPI0617436A2 (pt)	2011-07-26
DK1939204T6 (da)	2022-09-05
EP1939204B1 (en)	2013-01-02
RU2008119462A (ru)	2009-11-27
AU2006305271B2 (en)	2011-11-17
PL1939204T3 (pl)	2013-06-28
CA2624492C (en)	2014-02-18
TW200732309A (en)	2007-09-01
RU2418803C2 (ru)	2011-05-20
JP4955566B2 (ja)	2012-06-20
PT1939204E (pt)	2013-03-14
BRPI0617436B8 (pt)	2021-05-25
TWI400074B (zh)	2013-07-01
EP1939204A1 (en)	2008-07-02
US20090325900A1 (en)	2009-12-31
IL190754A (en)	2012-10-31
ES2398917T7 (es)	2022-10-26
JP2012102140A (ja)	2012-05-31
AU2006305271A1 (en)	2007-04-26
US9040693B2 (en)	2015-05-26
JPWO2007046392A1 (ja)	2009-04-23
NO20082249L (no)	2008-07-18
NO343185B1 (no)	2018-11-26
WO2007046392A1 (ja)	2007-04-26
JP5319797B2 (ja)	2013-10-16
KR20080063827A (ko)	2008-07-07
KR101384132B1 (ko)	2014-04-10
NL301202I1 (nl)	2022-11-09
SI1939204T1 (sl)	2013-05-31

Publication	Publication Date	Title
NL301202I2 (nl)	2023-01-24	Linzagolix, of een farmaceutisch aanvaardbaar zout daarvan, zoals linzagolix choline
NL301106I1 (nl)	2021-06-02	Cenobamaat of een farmaceutisch aanvaardbaar zout daarvan
NL301256I2 (nl)	2024-01-11	cedazuridine, of een farmaceutisch aanvaardbaar zout daarvan
NL301209I1 (nl)	2022-12-21	capmatinib of een farmaceutisch aanvaardbaar zout daarvan
NL301003I2 (nl)	2019-10-29	Sotagliflozin of een farmaceutisch aanvaardbaar zout daarvan
NL300993I2 (nl)	2019-07-11	Apalutamide of een farmaceutisch aanvaardbaar zout daarvan
NL301150I2 (nl)	2022-11-24	setmelanotide, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
NL301049I1 (nl)	2020-07-01	Crisaborale, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
NL301166I2 (nl)	2022-07-06	Avacopan of een farmaceutisch aanvaardbaar zout daarvan
NO2020038I1 (no)	2020-11-18	Ozanimod, or a pharmaceutically acceptable salt thereof, including the hydrochloride salt
NL301071I2 (nl)	2020-12-01	alpelisib of een farmaceutisch aanvaardbaar zout ervan
NL350108I2 (nl)	2022-12-07	Isofetamid of een zout daarvan
NL300886I2 (nl)	2017-10-24	baricitinib, of een farmaceutisch aanvaardbaar zout daarvan
NL301037I2 (nl)	2020-05-12	Solriamfetol of een farmaceutisch aanvaardbaar zout daarvan, bij voorkeur het hydrochloridezout daarvan
NL301261I2 (nl)	2024-03-25	Gefapixant, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout.
NL300865I1 (nl)	2017-03-14	Eluxadoline of een farmaceutisch aanvaardbaar zout ervan
NL301250I2 (nl)	2023-11-23	piflufolastat (18F) of een farmaceutisch aanvaardbaar zout daarvan
NL301042I1 (nl)	2020-06-17	Trifaroteen, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
NO2019027I1 (no)	2019-07-04	kobicistat eller et farmasøytisk akseptabelt salt derav
NL300990I2 (nl)	2019-07-11	Brigatinib, dan wel een farmaceutisch aanvaardbaar zout daarvan
NO2016016I1 (no)	2016-08-17	Lesinurad, eller et farmasøytisk akseptabelt salt derav
NO2018016I2 (no)	2018-05-14	Niraparib eller et farmasøytisk akseptabelt salt, stereoisomer eller tautomer derav
NL301021I2 (nl)	2020-04-14	talazoparib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout.
NL300946I2 (nl)	2018-09-26	Brexpiprazole, desgewenst in de vorm van een zout
NL301177I1 (nl)	2022-06-08	tecovirimat of een farmaceutisch aanvaardbaar zout daarvan